There are not any efficient drugs for treating dependence on cannabis.


To look at the security and efficacy of nabiximols within the therapy of sufferers with cannabis dependence.

Design, Setting, and Contributors:

This parallel double-blind randomized scientific trial evaluating nabiximols with placebo in a 12-week, multisite outpatient examine recruited individuals from February 3, 2016, to June 14, 2017, at Four outpatient specialist alcohol and drug therapy providers in New South Wales, Australia. Contributors had cannabis dependence (as outlined by the Worldwide Statistical Classification of Ailments and Associated Well being Issues, Tenth Revision) and have been looking for therapy, have been nonresponsive to prior therapy makes an attempt, have been 18 to 64 years of age, had no different substance use dysfunction, had no extreme medical or psychiatric situations, weren’t pregnant, weren’t mandated by a court docket to bear therapy, and supplied knowledgeable consent. Outcomes for major efficacy measures and all secondary outcomes have been obtained utilizing a modified intention-to-treat knowledge set.


Contributors acquired 12-week therapy involving weekly scientific evaluations, structured counseling, and versatile medicine doses-up to 32 sprays every day (tetrahydrocannabinol, 86.Four mg, and cannabidiol, 80 mg), allotted weekly.

Foremost Outcomes and Measures:

Major consequence was self-reported variety of days utilizing illicit cannabis through the 12-week interval. Different outcomes included alternate cannabis use parameters (intervals of abstinence, withdrawal, cravings, and issues), security parameters (opposed occasions and aberrant medicine use), well being standing, different substance use, and therapy retention.


A complete of 128 individuals (30 girls and 98 males; imply [SD] age, 35.0 [10.9] years) have been randomized and acquired not less than 1 dose of examine medicine. Contributors had used a imply (SD) of two.3 (2.1) g of cannabis on a imply (SD) of 25.7 (4.5) days previously 28 days. Remedy retention was comparable for the two teams (placebo, 30 of 67 individuals [44.8%]; nabiximols, 30 of 61 individuals [49.2%]), and each teams used comparable imply (SD) doses (placebo, 18.5 [9.5] sprays every day; nabiximols, 17.6 [9.5] sprays every day, equal to a imply [SD] of 47.5 [25.7] mg of tetrahydrocannabinol and 44.0 [23.8] mg of cannabidiol). For the first finish level, the placebo group reported considerably extra days utilizing cannabis through the 12 weeks (imply [SD], 53.1 [33.0] days) than the nabiximols group (imply [SD], 35.0 [32.4] days; estimated distinction, 18.6 days; 95% CI, 3.5-33.7 days; P = .02). Each teams confirmed comparable enhancements in well being standing, with no substantial adjustments in different substance use. Medicine was properly tolerated with few opposed occasions.

Conclusions and Relevance:

This examine demonstrates that cannabinoid agonist therapy, on this case utilizing nabiximols, together with psychosocial interventions is a protected method for decreasing cannabis use amongst people with cannabis dependence who’re looking for therapy.

Trial Registration: Identifier: ACTRN12616000103460.